Company news
Esperion Therapeutics, Inc. news in 2022
Esperion Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint
December 6, 2022
Esperion Appoints Ben Halladay Chief Financial Officer
November 15, 2022
Esperion Reports Third Quarter 2022 Financial Results and Provides Company Update
October 31, 2022
Esperion to Report Third Quarter 2022 Financial Results November 1, 2022
October 16, 2022
Esperion Announces Bempedoic Acid (NEXLETOL®) Recommended as Oral Non-Statin Therapy for LDL-Cholesterol Lowering in American College of Cardiology Expert Consensus Decision Pathway
August 25, 2022
Esperion Reports Second Quarter 2022 Financial Results and Provides Company Update
August 1, 2022
Esperion Announces Establishment of Scientific Advisory Board to Support Pipeline and Life Cycle Management
July 24, 2022
Esperion Announces the Appointment of J. Martin Carroll to its Board of Directors
May 31, 2022
Esperion Announces Five Abstracts Accepted for Presentation at the National Lipid Association Scientific Sessions
May 30, 2022
Esperion Reports First Quarter 2022 Financial Results and Provides Company Update
May 2, 2022
Esperion Announces Publication of CLEAR Harmony Open-Label Extension Study Data for Bempedoic Acid in the American Journal of Cardiology
May 1, 2022
Esperion Announces the Appointment of Stephen Rocamboli to its Board of Directors
April 27, 2022
Esperion to Report First Quarter 2022 Financial Results May 3, 2022
April 18, 2022
Esperion Announces Publication of Phase 3 Data for Bempedoic Acid in the Journal of Clinical Lipidology
April 12, 2022
Esperion Announces Two NEXLETOL® (bempedoic acid) Data Presentations at the American College of Cardiology’s 71st Annual Scientific Session & Expo
April 2, 2022
Esperion Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
February 21, 2022
Esperion to Report Fourth Quarter and Full Year 2021 Financial Results February 22, 2022
February 7, 2022
Esperion Provides Preliminary Fourth Quarter 2021 Financial Results and CLEAR Outcomes Program Update
January 10, 2022
Esperion Appoints Benjamin O. Looker as General Counsel
January 3, 2022
Calls in 2022
- Esperion Therapeutics (NASDAQ:ESPR) Q3 2022 Earnings Call
Nov 1, 2022
Transcript - Esperion Therapeutics (NASDAQ:ESPR) Q2 2022 Earnings Call
Aug 2, 2022
Transcript - Esperion Therapeutics (NASDAQ:ESPR) Q1 2022 Earnings Call
May 3, 2022
Transcript - Esperion Therapeutics (NASDAQ:ESPR) Q4 2021 Earnings Call
Feb 22, 2022
Transcript